Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants.
Saved in:
| Title: | Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants. |
|---|---|
| Authors: | Chen JF; Department of Evidence-Based Medicine and Clinical Epidemiology, Second Clinical College of Wuhan University, Wuhan, China., Xiao LF, Zhang R, Zeng ZH, Li YX, Meng XY |
| Source: | Acta haematologica [Acta Haematol] 2017; Vol. 137 (4), pp. 207-208. Date of Electronic Publication: 2017 May 05. |
| Publication Type: | Journal Article; Comment |
| Journal Info: | Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662 (Electronic) Linking ISSN: 00015792 NLM ISO Abbreviation: Acta Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1421-9662 |
|---|---|
| DOI: | 10.1159/000471839 |
